Epirubicin micelle formulation - NanoCarrier/Kowa

Drug Profile

Epirubicin micelle formulation - NanoCarrier/Kowa

Alternative Names: K-912; NC 6003; NC-6300

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator NanoCarrier
  • Developer Kowa; NanoCarrier
  • Class Cytostatic antibiotics; Doxorubicins
  • Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Jun 2017 NanoCarrier plans a phase I/II trial for Solid tumours and Soft tissue sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (NCT03168061)
  • 17 Oct 2016 Kowa and NanoCarrier completes a phase I trial in Solid tumours in Japan (JapicCTI132221)
  • 27 Apr 2016 Phase I development is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top